Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (June 2018)
35 slides from Adocia SA's investor presentation, June 2018

Slide 1: Adocia Corporate Presentation June 2018
ADOCIA INNOVATIVE MEDICINE FOR EVERYONE, EVERYWHERE Corporate Presentation June 2018

Slide 2: Disclaimer
INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t

Slide 3: ADOCIA in summary
ADOCIA ADOCIA in summary Business model delivers cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical diabetes assets including ultra-rapid insulin BC Lispro, modern premix 2 BC Combo, ready-to-use BC Glucagon, and BC Pramlintide Insulin 3 $135M li

Slide 4: Adocia's management and team
ADOCIA Adocia’s management and team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & Legal US General Manager Co-founder R&D Director Co-founder Co-founder ▪ Focused on del

Slide 5: BioChaperone Technology
BIOCHAPERONE TECHNOLOGY 5 June 2018

Slide 6: BioChaperone unlocks the potential of proteins and peptides
ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon, teduglutide…) [BioChaperone® Protein] Complex ✓ Improved solubility ✓Improved stabi

Slide 7: BioChaperone-enabled innovation in diabetes and beyond
ADOCIA BioChaperone-enabled innovation in diabetes and beyond Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC GLP-2 Short Bowel Syndrome Hi

Slide 8: Adocia Lead Insulin Programs
ADOCIA LEAD INSULIN PROGRAMS BIOCHAPERONE LISPRO & BIOCHAPERONE COMBO 8 June 2018

Slide 9: People with diabetes require simpler, more physiologic treatments
MARKET People with diabetes require simpler, more physiologic treatments 415M 1 26M2 ▪ Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue people with on insulin diabetes in 2015 ▪ There is a need to address the underlying complexity of diabetes ▪ With mor

Slide 10: BioChaperone insulins fit the need for innovation in a rapidly evolving insulin market
MARKET BioChaperone Insulins formulations fit the need for innovation in a rapidly evolving insulin market ▪ Diabetes injectable drugs market growth is driven by innovation: ▪ Drugs: ultra-rapid insulin, multi-agent combinations, co-agonists… ▪ Diabetes management: development of integrated solution

Slide 11: Adocia and Tonghua Dongbao entered a strategic alliance
TONGHUA Adocia and Tonghua Dongbao entered a strategic DONGBAO alliance to develop best-in-class insulins ▪ Adocia and Tonghua Dongbao (THDB) strategic alliance: ✓ Licensing agreements for BioChaperone (BC) Lispro & BC Combo ✓ Supply agreements for insulins glargine and insulin lispro ▪ THDB is the

Slide 12: Strategic licensing deals with THDB for BC Lispro & BC Combo
LICENSE Strategic licensing deals with THDB for BC Lispro & BC Combo on Chinese market >100M1 ▪ Large and underserved Chinese insulin market features multiple drivers for growth People with ▪ Rapidly growing (CAGR 12%)2, with the number of treated patients set to double in the diabetes in 65%2 next

Slide 13: Strategic supply agreement with THDB opens global opportunities
SUPPLY Strategic supply agreement with THDB opens global opportunities for Adocia ▪ With access to stable, high-quality insulin lispro and insulin glargine supplies, Adocia now gains full control over BC Lispro and BC Combo development ▪ Partnering opportunities are multiplied: ✓ Companies focused o

Slide 14: BC Lispro: ultra-rapid insulin with best-in-class potential
Licensed to THDB in China BC LISPRO Ultra-rapid insulin with potential for best-in-class ▪ BioChaperone® Lispro could be a differentiated competitor to Fiasp® (1st approved ultra-rapid insulin, Novo Nordisk). ▪ Consistently faster-on and faster-off metabolic effect vs. Humalog® & Novolog® in 252 peo

Slide 15: Ultra-rapid insulin is a key element to close the loop
BC LISPRO Ultra-rapid insulin with fast-on and fast-off profile is a key element to « close the loop » Adocia intends to initiate Smart CGM its first Phase 3 trial in the Pumps & pens insulin pump setting 15 June 2018

Slide 16: BC Combo: alternative to premix insulin for type 2 diabetes
Licensed BC COMBO A safer and more efficient alternative to premix to THDB in China insulin for the treatment of type 2 diabetes ▪ Premix products are easier to use than basal-bolus regimens but present $5B inferior prandial coverage and a higher risk of hypoglycemia Premix insulin market (2016)1 ▪

Slide 17: Multihormonal Treatments for Diabetes
MULTIHORMONAL TREATMENTS FOR DIABETES NEXT GENERATION OF CARE FOR BETTER OUTCOMES 17 June 2018

Slide 18: Multi-hormonal approaches to improve diabetes and obesity management
RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se

Slide 19: Time-sensitive hormonal pattern maintains normo-glycemia
DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

Slide 20: BC Pramlintide Insulin: next generation prandial treatment in T1D
BC PRAM Next generation of prandial treatment to improve long- INSULIN term outcomes in T1D 79%2 Of diabetics live ▪ BioChaperone Pramlintide Insulin exceptionally tight prandial with severe control1,2,3, potentially lowering the risk of long-term severe complications complications ▪ Multiple hormon

Slide 21: Ready-to-use aqueous formulation of human glucagon
BC A ready-to-use aqueous formulation of human glucagon GLUCAGON for acute and chronic use ▪ BioChaperone Glucagon is a ready-to-use aqueous formulation of $400M human glucagon supporting: Forecasted ▪ Rescue treatment of severe hypoglycemia in a ready-to-use market in 20251 autoinjector: current gl

Slide 22: Expanding the Portfolio
EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE TRACK-RECORD AND VERSATILITY TO ADDRESS NEW THERAPEUTIC TARGETS 22 June 2018

Slide 23: BioChaperone improves approved or NCE proteins and peptides
BC BioChaperone can be used to improve both approved PLATFORM or NCE proteins and peptides BioChaperone/Protein complex ▪ Leveraging Adocia core competencies in protein and peptide formulation to fit partner’s needs ▪ More than 20 clinical trials (Phase 1-3) to date on 6 different pharmaceutical pro

Slide 24: Expanding the use of BioChaperone platform
PIPELINE EXPANSION Expanding the use of BioChaperone platform ▪ BioChaperone Glucagon GLP-1 for the treatment of obesity ▪ Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of more aggressive treatment regimens: 36.5%1 of US adults are ▪ Based on BC Glucagon, Ado

Slide 25: Key financial elements
ADOCIA Key financial elements Financial summary Shareholders’ equity (May 2018) Analysts ▪ Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 % ▪ Jefferies (Peter Welford) 59.6% ▪ Kepler Market (Arsène Guekam) ▪ 6.9M shares outstanding ▪ Oddo (Sébastien Malafosse – Pierre Corby) ▪ Louis Ca

Slide 26: Expected News Flow
ADOCIA Expected News Flow Pipeline Conferences ▪ BC HUMAN GLUCAGON Adocia will present at the American Diabetes Association 78th ▪ Phase 1/2 expected to launch in H2 18 Scientific Sessions in Orlando, Florida, June 22nd-June 26th: ▪ BC PRAMLINTIDE INSULIN ▪ 2 oral presentations ▪ Results of first-in

Slide 27: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 27 June 2018

Slide 28: Appendix
APPENDIX 28 June 2018 ADOCIA f-

Slide 29: Adocia is supported by a top-tier Medical Advisory Board
ADOCIA Adocia is supported by a top-tier Medical Advisory Board ▪ Dr. Jay Skyler, MD, Chairman, University of Miami (US) ▪ Dr. Vanita Aroda, MD, MedStar Health Research Institute (US) ▪ Dr. Bruce Bode, MD, Emory University (US) ▪ Dr. John Buse, MD, PhD, University of North Carolina (US) ▪ Dr. Eda Ce

Slide 30: HinsBet: affordable prandial insulin for price-sensitive populations
HINSBET Affordable prandial insulin for price-sensitive populations $1B Human prandial ▪ HinsBet is a formulation of human insulin designed to act as rapidly as insulin market an insulin analog (2016)1 ▪ Human insulin is the most common prandial insulin choice in low- income countries, but diffuses

Slide 31: Efficient and affordable intensification options over basal insulin for T2D
BC Efficient and affordable intensification options over GLAR GLP-1 basal insulin for T2D $2.2B1 2023 Forecast ▪ Combinations of basal insulin and GLP-1 are a new class of treatment for T2D Basal-GLP1 ▪ 50% patients are not controlled on basal insulin alone2 market ▪ 2 products recently approved in

Slide 32: BC Lispro results compared to Humalog U100 in T1DM
BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX ▪ BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo

Slide 33: BC Combo results compared to Lispro Mix 75/25 in T1DM
BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL ▪ In this solid mixed

Slide 34: BC Combo results compared to Humalog 75/25 in T2DM
BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone ▪ In t

Slide 35: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 35 June 2018
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025